We are pleased to share news that everolimus (Afinitor) for epilepsy has been added to Australia’s pharmaceutical benefits scheme (PBS). Today the Federal Health Minister, the Honourable Greg Hunt announced that this medicine to treat seizures for people with TSC … Read More
We are pleased to share news that Everolimus (Afinitor) for epilepsy has been given a positive recommendation by the pharmaceutical benefits advisory committee (PBAC). This is a recommendation to the Federal Health Minister to add this medicine to the pharmaceutical … Read More
Today we celebrate the academic publication of results from the Treatment trial. This research developed a topical cream to treat the small tumours that grow on the face of people with tuberous sclerosis. While these tumours, called angiofibromas, do … Read More
Thank you to all the members of the TSC community who made a contribution to our draft submission to the pharmaceutical benefits advisory committee (PBAC). The submission to include Afinitor (Everolimus, an mTOR inhibitor medicine) on the pharmaceutical benefits scheme (PBS) … Read More
In December, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider an application from Novartis for Everolimus/Afinitor to be listed on the Pharmaceutical Benefits Scheme (PBS) for people with TSC who are experiencing seizures that do not respond well to available … Read More
In July, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider an application from Novartis for Everolimus/Afinitor to be listed on the Pharmaceutical Benefits Scheme (PBS) for people with TSC who are experiencing seizures that do not respond well to available … Read More
We’ve updated our information on the availability of this new treatment for facial angiofibromas.
The Elizabeth Pinkerton Memorial award is given annually by TSA to a health professional to recognise their efforts to improve the lives of TSC affected families in Australia. Nominations close on Friday 29th July.
Do you want an easier way to explain tuberous sclerosis to people you meet? These small business cards provide a brief explanation of TSC and direct people to Tuberous Sclerosis Australia’s website to learn more. There is space to write … Read More
Topical Rapamycin is an experimental treatment for facial angiofibromas, which affect the majority of people with Tuberous Sclerosis. A formal clinical trial, funded by generous donors to Tuberous Sclerosis Australia, has completed at Sydney Children’s Hospital which aims to provide … Read More